Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 03:50PM GMT
Release Date Price: $73.3 (-2.27%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Good morning from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, and it's my pleasure to introduce our next company, Editas Medicine and CEO, Cindy Collins.

Please note that following this presentation, we will have a Q&A session where you have the ability to submit questions via the conference portal. So with that, Cindy, thank you for being here today, and let me turn things over to you.

Cynthia Collins

Thank you, Cory, and the JPMorgan team for the opportunity to speak today. Next slide. I would like to draw your attention to the fact that this presentation contains forward-looking statements. We encourage you to review potential risks and uncertainties outlined in our most recent 10-Q and 10-K, which are on file with the SEC. Next slide. Last year was a revolutionary year for gene editing.

There were important accomplishments and remarkable strides made towards potentially curative medicines for what were once thought to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot